logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11090335 B1

PDFFull Text
Date of Patent:
Aug. 17, 2021

Filed:

Aug. 30, 2018

Chimeric antigen receptor targeting human nkg2dl and methods of preparing said receptor and pharmaceutical composition

Applicant:

Nanjing Kaedi Biotherapeutics Ltd., Nanjing, CN;

Inventors:

Hongjiu Dai, Shanghai, CN;

Bin Sun, Kunming, CN;

Xudong Zhao, Shanghai, CN;

Assignee:

NANJING KAEDI BIOTHERAPEUTICS LTD., Nanjing, CN;

Attorney:

Bayramoglu Law Offices LLC

Primary Examiner:

Robert S Landsman

Int. Cl.
CPC ...
C12N 15/11 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C12N 15/63 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C12N 15/62 (2006.01); A61K 9/00 (2006.01); C07K 14/47 (2006.01); C12N 5/16 (2006.01); A61P 37/06 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 9/0019 (2013.01); A61K 39/001112 (2018.08); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 14/4726 (2013.01); C07K 14/7051 (2013.01); C07K 14/7056 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 5/163 (2013.01); C12N 15/111 (2013.01); C12N 15/62 (2013.01); C12N 15/625 (2013.01); C12N 15/63 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/80 (2018.08); A61K 2039/812 (2018.08); A61K 2039/828 (2018.08); A61K 2039/844 (2018.08); A61K 2039/852 (2018.08); A61K 2039/86 (2018.08); A61K 2039/884 (2018.08); A61K 2039/892 (2018.08); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/32 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01); C12N 2740/16043 (2013.01);
Abstract

A chimeric antigen receptor targeting to human NKG2DL, its encoding sequence, and its modified immune response cells, and the preparation and application thereof are provided. This invention constructs a chimeric antigen receptor targeting to NKG2DL and its modified immune response cell based on the NKG2D molecule. The amino acid sequence of the chimeric antigen receptor targeting the human NKG2DL is sequentially connected by the following amino acid sequences from an amino terminal to a carboxy terminal: an amino acid sequence of a guiding sequence, an amino acid sequence of human NKG2D, an amino acid sequence of a human CD8 hinge region, an amino acid sequence of a human CD8 transmembrane region, an amino acid sequence of a human 4-1BB intracellular domain and an amino acid sequence of a human CD3 zeta domain.

Find Patent Forward Citations

Dai, Hongjiu. (2021). Chimeric antigen receptor targeting human nkg2dl and methods of preparing said receptor and pharmaceutical composition (U.S. Patent No. 11090335). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11090335

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…